Lilly lung cancer drug improves survival in late-stage trial

[riky]

Lilly lung cancer drug improves survival in late-stage trial

An experimental cancer drug developed by Eli Lilly and Co, touted by some to be the company's next blockbuster, significantly improved survival rates in lung cancer patients, sending the company's shares up 3 percent in early trading. Lilly needs new drugs to offset declining sales of its older drugs as they lose patent protection. The drug has already been shown be successful in treating stomach cancer, and Lilly is waiting for approval from the U.S. Food and Drug Administration to market it for that disease. The latest results could help allay some concerns about the drug after it failed to delay the progression of breast cancer in a late-stage trial last year.

Source: You are not allowed to view links. Register or Login